Drug Profile
Research programme: cancer and autoimmune disorder therapeutics - Gliknik
Alternative Names: CD20 Stradobody; GB-4542; Rituximab biobetter - Gliknik; Stradobodies™; Stradomers™Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Gliknik
- Class
- Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 03 Mar 2016 Preclinical development is ongoing for Cancer and Autoimmune disorders in USA